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Natural killer (NK) T cells are a subset of mature T lym-
 
phocytes that express an 
 
a/b
 
 TCR together with markers
characteristic of NK cells such as NK1.1 (1, 2). In contrast
to conventional T cells, which recognize small peptides
bound to polymorphic MHC class I or class II molecules,
TCRs on NK T cells recognize glycolipids associated with
the monomorphic MHC-like CD1d molecule. As ex-
pected from their restricted specificity, most NK T cells
utilize a limited TCR repertoire comprising an invariant
V
 
a
 
14–J
 
a
 
281 chain paired preferentially to V
 
b
 
8.2 (in the
mouse) or the homologous invariant V
 
a
 
24–J
 
a
 
Q chain
paired to V
 
b
 
11 in humans.
At present, the physiological CD1d-associated ligands
recognized by the semiinvariant TCR on NK T cells are
not known. However a synthetic glycolipid, 
 
a
 
-galactosyl-
ceramide (
 
a
 
-GalCer) has been shown to selectively activate
NK T cells expressing the V
 
a
 
14/V
 
b
 
8.2 (or V
 
a
 
24/V
 
b
 
11)
TCR complex (3). As 
 
a
 
-GalCer is normally found in ma-
rine sponges (but not mammalian cells), it is generally be-
lieved that the physiological ligand of the semiinvariant
TCR on NK T cells is an as yet unidentified glycolipid
with a high degree of structural homology to 
 
a
 
-GalCer.
A striking feature of NK T cells is their ability to rapidly
produce large amounts of cytokines upon TCR engage-
ment. Although cytokine production by NK T cells was
initially believed to follow a Th2 pattern (dominated by
IL-4; reference 4), it is now generally accepted that NK T
cells can also secrete large quantities of IFN-
 
g
 
 and thus do
not readily fit the Th1/Th2 paradigm. As expected from
their phenotype, NK T cells also share functional proper-
ties with NK cells such as the ability to kill certain target
cells such as tumor cells and immature thymocytes.
Despite their relatively well characterized functional
properties in vitro, the physiological role of NK T cells in
vivo remains to be established. In this respect, NK T cells
are protective in immune responses to certain tumors and
parasites and appear to play an important regulatory role in
inhibiting the development of autoimmune disorders.
Clearly the identification of physiological CD1d-associated
glycolipid ligands (of either endogenous or exogenous ori-
gin) will be required to put NK T cells into a better de-
fined context in homeostasis or pathology.
A major problem in NK T cell biology to date has been
the lack of appropriate reagents to selectively identify
CD1d-dependent NK T cells among heterogeneous lym-
phoid populations in vivo. In the mouse, the NK1.1
marker itself (a member of the NKR-P1 gene family) is
polymorphic and only expressed by a very limited number
of inbred mouse strains. Moreover, there is recent evidence
 
that some NK1.1
 
1
 
 T cells do not express the canonical
V
 
a
 
14/V
 
b
 
8.2 TCR and in fact recognize CD1d-indepen-
dent ligands (5–7). Although these problems could in the-
ory be largely overcome by mAbs specific for the semiin-
variant TCR chains on NK T cells, this is not possible in
practice, as anti-V
 
b
 
8.2 antibodies stain a large fraction of
conventional T cells and the only published anti-V
 
a
 
14
mAb (8) is of controversial specificity (1). The situation in
humans is somewhat different, as mAbs against both V
 
a
 
24
and V
 
b
 
11 exist (9). Nevertheless, only a fraction of all
V
 
a
 
24
 
1
 
 or V
 
b
 
11
 
1
 
 T cells are NK T cells, and even a dou-
ble staining procedure to selectively identify V
 
a
 
24
 
1
 
V
 
b
 
11
 
1
 
cells cannot exclude conventional T cells that rearrange
V
 
a
 
24 to J regions other than J
 
a
 
Q.
To circumvent these problems, Matsuda et al. (10) in
this issue (as well as Benlagha et al. [11] in the June 5 issue)
have succeeded in producing tetrameric CD1d–glycolipid
complexes that bind selectively to NK T cells expressing
the semiinvariant V
 
a
 
14/V
 
b
 
8.2 or V
 
a
 
24/V
 
b
 
11 TCR.
 
CD1d–
 
a
 
-GalCer Tetramers.
 
Tetramer technology was
initially devised as a way of visualizing CD8
 
1
 
 T cells ex-
pressing TCRs specific for a given MHC class I–peptide
complex. Although the specific peptides seen by a wide va-
riety of TCRs on CD8
 
1
 
 cells had been known for some
time, the interactions of monomeric MHC class I–peptide
complexes with the TCR were of too low an affinity to re-
sult in stable binding. This problem was solved by Altman
et al. (12), who engineered a unique bacterial biotinylation
substrate at the COOH terminus of recombinant MHC
class I molecules. Refolding of biotinylated heavy chains
with specific peptides and subsequent incubation with fluo-
rescent avidin resulted in the formation of tetrameric MHC
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class I–peptide complexes that bound stably and specifically
to the appropriate TCR. This method has subsequently
been extended to produce fluorescent tetramers of peptides
bound to MHC class Ib molecules such as Qa-1
 
b
 
 and
HLA-E (which bind to specific receptors on subsets of NK
cells) as well as MHC class II–peptide tetramers, which
bind to TCR on CD4
 
1
 
 T cells (13–15).
Despite recent reports of fluorescent tetramers incorpo-
rating MHC class Ib molecules, the successful production
of CD1d–glycolipid tetramers by Matsuda et al. (10) and
Benlagha et al. (11) was somewhat unexpected. In the first
place, all previous MHC heavy chains had been refolded
with well characterized short peptides that could be pro-
duced in large quantity and high purity, and in many cases
the crystal structure of the relevant MHC–peptide complex
was known. In contrast, although the crystal structure of
recombinant mouse CD1d had been solved (16), very little
was known about the potential physical interactions be-
tween glycolipids and CD1d molecules. Even worse, pre-
liminary attempts to measure the strength of interactions
between purified CD1d molecules and 
 
a
 
-GalCer by plas-
mon resonance technology had indicated a very short half-
life (17), thereby suggesting that the production of stable
tetramers might be difficult if not impossible. Fortunately,
these concerns turned out to be premature, and it appears
in retrospect that fluorescent CD1d–
 
a
 
-GalCer tetramers
are relatively stable. Whatever the explanation for this dis-
crepancy (and both papers give their versions), it is proba-
bly instructive in highlighting the limits of plasmon reso-
nance measurements, particularly when nonpeptidic ligands
are involved.
 
NK T Cell Subsets.
 
Arguably the most important ex-
perimental finding emanating from this first description of
fluorescent CD1d–
 
a
 
-GalCer tetramers is a clearer defini-
tion of the heterogeneity of the NK T cell population it-
self. As mentioned previously, prototypic NK T cells in the
mouse (as defined in an appropriate inbred strain such as
C57BL/6) express NK1.1 together with semiinvariant
V
 
a
 
14/V
 
b
 
8.2 TCRs and are selected by CD1d during their
development. Nevertheless, recent studies from several
groups had suggested that some NK1.1-expressing T cells
arise independently of CD1d and apparently do not express
the semiinvariant TCRs (5–7). Conversely, indirect evi-
dence supporting the existence of a CD1d-specific but
NK1.1
 
2 
 
T cell subset expressing a semiinvariant TCR had
also been reported (18).
 
This confusion has now been clearly resolved by the
studies of Matsuda et al. (10) and Benlagha et al. (11). Both
groups provide definitive evidence for the presence of
three distinct T cell subsets defined by simultaneous stain-
ing with NK1.1 and CD1d–
 
a
 
-GalCer tetramers (Table I).
Prototypic NK T cells (NK1.1
 
1
 
, tetramer positive) express
the semiinvariant TCR and are absent in CD1d-deficient
mice. Furthermore, as predicted by earlier studies (5–7),
NK1.1
 
1
 
 tetramer-positive cells localize preferentially to
thymus and liver and are mainly of the CD4
 
1
 
 or (to a lesser
extent) CD4
 
2
 
CD8
 
2
 
 phenotype.
A second T cell subpopulation expresses NK1.1 but does
not stain with fluorescent CD1d–
 
a
 
-GalCer tetramers (Ta-
ble I). Consistent with their tetramer-negative phenotype,
these cells do not express the semiinvariant TCR (indeed
they appear to express TCR V
 
a
 
 and V
 
b
 
 domains at ran-
dom) and do not depend upon CD1d for their develop-
ment. NK1.1
 
1
 
 tetramer-negative cells are relatively more
abundant in spleen and bone marrow (as opposed to thy-
mus and liver), and most are of the CD8
 
1
 
 or CD4
 
2
 
CD8
 
2
 
phenotype. Again, these conclusions are largely consistent
with the predictions of other earlier studies (5–7).
The third (and potentially most novel) T cell subset
defined by Matsuda et al. (10) and Benlagha et al. (11)
are NK1.1
 
2
 
 but tetramer positive (Table I). Despite the
absence of NK1.1 expression, these cells are CD1d de-
pendent and express semiinvariant TCRs, as would be
expected from their ability to bind CD1d–
 
a
 
-GalCer
tetramers. The CD4/CD8 phenotype of NK1.1
 
2
 
 tet-
ramer-positive cells is very similar to that of prototypic
NK T cells (mostly CD4
 
1
 
 with some CD4
 
2
 
CD8
 
2
 
), indi-
cating that coreceptor expression is tightly linked to selec-
tion by CD1d. Of particular interest is the fact that
NK1.1
 
2
 
 tetramer-positive cells have a unique tissue distri-
bution with respect to the other two subsets. Although
present to some extent in typical organs where NK T cells
localize (thymus, liver, bone marrow, and spleen), these
cells represent the vast majority of tetramer-positive cells
in lymph nodes and in the small intestine. Importantly,
NK T cells have traditionally been considered to be absent
from these latter tissues. Further experiments will be re-
quired to assess the physiological significance of NK1.1
 
2
 
tetramer-positive cells in the gut epithelium. In this re-
gard, it is noteworthy that the NK1.1
 
2
 
 (but not NK1.1
 
1
 
)
subset of tetramer-positive cells expresses the CD49d (
 
a
 
4
integrin) homing receptor (11) and that the gut epithelium
 
Table I.
 
NK T Cell Subsets Defined by CD1d: 
 
a
 
-GalCer Tetramers and NK1.1
 
Property
NK1.1
 
1
 
 
tetramer positive
NK1.1
 
1
 
 
tetramer negative
NK1.1
 
2
 
 
tetramer positive
TCR repertoire V
 
a
 
14/V
 
b
 
8.2 Diverse V
 
a
 
14/V
 
b
 
8.2
Selecting ligand CD1d ? (not CD1d) CD1d
Coreceptor expression CD4 or CD4
 
2
 
CD8
 
2
 
CD8 or CD4
 
2
 
CD8
 
2
 
CD4 or CD4
 
2
 
CD8
 
2
 
Tissue preference Thymus, liver Spleen, bone marrow Intestine, lymph node
 F17
 
MacDonald
 
has previously been reported to express high levels of
CD1d (19).
 
NK T Cell Development.
 
The developmental origin of
prototypic NK T cells expressing the semiinvariant V
 
a
 
14/
V
 
b
 
8.2 TCR remains enigmatic. Although a number of
early studies suggested an important role for extrathymic
NK T cell development (particularly in the liver), more re-
cent reports strongly suggest that most CD1d-dependent
NK T cells are thymus derived (20, 21). Assuming this to
be the case, an important issue is whether thymic NK T
cells arise as a byproduct of conventional T cell develop-
ment or alternatively differentiate along an independent in-
trathymic NK T cell lineage. According to the first scenario
(mainstream model), T cell precursors that randomly rear-
range their TCR-
 
a
 
 genes and express the semiinvariant
TCR at the CD4
 
1
 
CD8
 
1
 
 stage of development would ac-
quire the NK T cell phenotype, presumably as a conse-
quence of unique aspects of TCR signaling mediated by
CD1d–glycolipid recognition. In the second model, a sepa-
rate lineage of committed NK T precursor cells would be
rescued from cell death upon expression of the semiinvari-
ant TCR and recognition of CD1d. As current evidence
does not support a directed V
 
a
 
14 rearrangement mecha-
nism in NK T cells (22), the mainstream model is easier to
reconcile with the extremely low probability (estimated to
be 
 
z
 
1:50,000) of randomly rearranging the semiinvariant
TCR during development (1).
Any model of NK T cell development must account for
the peculiar coreceptor expression pattern of mature
CD1d-dependent NK T cells. As described previously
(5–7) and emphasized by the current detailed analysis of
CD1d–
 
a
 
-GalCer tetramer–positive cells (10, 11), CD1d-
dependent NK T cells in all tissues analyzed (irrespective of
NK1.1 expression) consist of a majority (60–80%) of CD4
 
1
 
cells, with the remaining cells being CD4
 
2
 
CD8
 
2
 
. Essen-
tially no CD8
 
1
 
 tetramer-positive cells can be detected. If
the mainstream model for NK T cell development is cor-
rect, this in turn implies that CD4
 
1
 
CD8
 
1
 
 precursors ex-
pressing the semiinvariant TCR can give rise to either
CD4
 
1
 
or CD4
 
2
 
CD8
 
2
 
 (but not CD8
 
1
 
) progeny upon
CD1d recognition.
A speculative version of the mainstream model for
CD1d-dependent NK T cell development is presented in
Fig. 1. This model is similar to that proposed earlier by
Bendelac et al. (1) in the sense that it assumes that CD8
 
1
 
NK T cells cannot fully mature (presumably because CD8
expression contributes to the avidity of CD1d recognition
by immature NK T cells and thus leads to negative selec-
tion). However, the model differs from earlier versions in
that it proposes a critical stage of thymus development at
which mainstream CD4
 
1
 
CD8
 
1
 
 precursor cells become ir-
reversibly committed to the CD4 lineage. According to
this model, CD4
 
1
 
CD8
 
1
 
 precursors that interact produc-
tively with CD1d before lineage commitment will down-
regulate both CD4 and CD8 and emerge as CD4
 
2
 
CD8
 
2
mature NK T cells. In contrast, CD41CD81 precursors
that recognize CD1d only after lineage commitment has
occurred will follow a predetermined developmental pro-
gram involving selective CD8 downregulation and emerge
as CD41 mature NK T cells.
Two observations arising from the current studies of
CD1d–a-GalCer tetramers are potentially relevant to the
mainstream model of NK T cell development outlined in
Fig. 1. First, Matsuda et al. (10) show that a small propor-
tion of tetramer-positive cells in the thymus have a
CD41CD81 phenotype. If confirmed, this finding would
provide the first direct quantitative estimate (z1/2,000) for
the frequency of CD1d–a-GalCer–binding cells within the
CD41CD81 immature thymocyte population. Such cells
would be obvious candidate precursors of mature NK T
cells. Second, Benlagha et al. (11) show that the coreceptor
phenotype of mature tetramer-positive NK T cells is radi-
cally altered in transgenic mice overexpressing the invariant
Va14 chain (and containing elevated numbers of tetramer-
positive cells). Instead of the usual predominance of CD41
cells observed in the tetramer-positive subset in normal
mice, tetramer-positive cells in Va14-transgenic mice are
almost exclusively CD42CD82. In the context of the
model proposed in Fig. 1, these latter data could be inter-
preted to mean that premature expression of the semiin-
variant TCR in the thymi of Va14-transgenic mice leads
to preferential selection of CD1d-dependent NK T cells
before the lineage commitment checkpoint and conse-
quently an enrichment for the CD42CD82 phenotype.
Another independent finding that is consistent with the
model depicted in Fig. 1 is that CD42CD82 NK T cells
arise before CD41 NK T cells during neonatal ontogeny
(Lees, R.K., and H.R. MacDonald, unpublished data).
NK T Cell Homeostasis. Another aspect of NK T cell
biology that is amenable to analysis with CD1d–a-GalCer
tetramers is homeostasis. In this respect, it was recently re-
Figure 1. Speculative model of thymic NK T cell development. The
model attempts to account for the unusual coreceptor expression pattern
of CD1d-dependent NK T cells as a byproduct of mainstream T cell de-
velopment. The hatched line represents a putative stage where
CD41CD81 thymocytes become irreversibly committed to the CD4 or
CD8 lineage.
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ported that NK T cells in the liver (and to a lesser extent
the spleen) are extremely sensitive to activation-induced
cell death upon TCR engagement by low doses of anti-
CD3 antibodies (23). Matsuda et al. (10) have now con-
firmed and extended these findings by showing that treat-
ment of mice with a-GalCer induces a rapid disappearance
of tetramer-positive cells that is most marked in the liver.
In apparent contrast to earlier data (23), regeneration of tet-
ramer-positive cells in the liver after a-GalCer treatment
seems to be relatively slow. Further experiments monitor-
ing CD1d–a-GalCer tetramer–positive cells in vivo after
diverse stimuli should provide novel insights into the dy-
namics and homeostasis of NK T cells.
Future Perspectives. Aside from their obvious impor-
tance in studying NK T cell development and homeostasis
in normal mice, CD1d–a-GalCer tetramers should prove
to be extremely useful for monitoring NK T cells in a wide
spectrum of immune responses in vivo as well as in patho-
logical situations such as autoimmune disorders. A major
strength of the tetramer technology is that CD1d molecules
are sufficiently conserved between mice and humans so
that CD1d–a-GalCer tetramers cross-react efficiently with
the semiinvariant TCRs of the two species (11). This con-
servation should facilitate the optimization of CD1d–a-
GalCer tetramer production so that NK T cells can be effi-
ciently monitored in blood (or tissue biopsies) of patients
during the course of treatment for tumors or autoimmune
diseases. In the mouse, CD1d–a-GalCer tetramers should
prove indispensable for monitoring NK T cells in the vast
majority of inbred strains where the NK1.1 allele is not ex-
pressed. Importantly, the list of NK1.12 strains to be ana-
lyzed with tetramers includes BALB/c (the prototype strain
for Th2 responses) and the nonobese diabetic mouse,
where a role for NK T cells in the control of autoimmune
diabetes has been indirectly established (24, 25).
Finally, it is perhaps pertinent to speculate on the
broader implications of fluorescent tetramer technology as
it applies to CD1–lipid interactions. In this context, it
should be noted that mouse CD1d can apparently bind and
present lipids distinct from a-GalCer (such as phospholip-
ids) to T cells not expressing the semiinvariant TCR (26).
Moreover, in contrast to mice, humans (and most other
mammals analyzed to date) express multiple members of
the CD1 family in addition to CD1d. Importantly, presen-
tation of glycolipids appears to be a general property of
CD1 molecules. Indeed it is well established that glycolipid
components of mycobacterial cell walls such as mycolic
acid and lipoarabinomannan are presented to T cells via
human CD1b (27), and recent evidence suggests that hu-
man CD1c may also bind and present isoprenoid glycolip-
ids of mycobacterial origin (28). An obvious future goal of
the tetramer technology ushered in by Matsuda et al. (10)
and Benlagha et al. (11) will be to produce novel tetramers
composed of other glycolipids bound to different CD1
molecules. If successful, this approach may revolutionize
our perspective of the scope and importance of the CD1
antigen presentation pathway.
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